CARDIO DIAGNOSTICS HOLDINGS, INC. Cardio Diagnostics Holdings, Inc. Share Price
Equities
CDIO
US14159C1036
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.691 USD | +0.14% |
|
-6.57% | -71.90% |
| Sales 2024 * | 612K 51.09M | Sales 2025 * | 1.8M 150M | Capitalization | 14.9M 1.24B |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -751M | Net income 2025 * | -7M -584M | EV / Sales 2024 * | 24.3 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.28 x |
| P/E ratio 2024 * |
-1.59
x | P/E ratio 2025 * |
-2.03
x | Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.25% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.72% | ||
| 1 week | -6.57% | ||
| Current month | -50.72% | ||
| 1 month | -49.65% | ||
| 3 months | -65.36% | ||
| 6 months | +228.24% | ||
| Current year | -71.90% |
1 week
0.65
0.82
1 month
0.651.43
Current year
0.653.56
1 year
0.173.56
3 years
0.1710.25
5 years
0.1710.25
10 years
0.1710.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 35 | 25/22/25 | |
Elisa Luqman
DFI | Director of Finance/CFO | 59 | 25/22/25 |
Timur Dogan
CTO | Chief Tech/Sci/R&D Officer | 36 | 25/22/25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 52 | 25/22/25 | |
Oded Levy
BRD | Director/Board Member | 63 | 25/22/25 |
Paul Burton
BRD | Director/Board Member | - | 21/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 0.691 | +0.14% | 490 616 |
| 26/24/26 | 0.69 | -4.49% | 449,811 |
| 25/24/25 | 0.7224 | -3.68% | 306,433 |
| 24/24/24 | 0.75 | -0.20% | 117,699 |
| 23/24/23 | 0.7515 | +0.33% | 259,587 |
Delayed Quote Nasdaq, April 30, 2024 at 12:51 am IST
More quotes
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.69
USD
Average target price
4.675
USD
Spread / Average Target
+577.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -71.90% | 14.9M | |
| -2.84% | 103B | |
| +1.35% | 95.28B | |
| +1.46% | 22.15B | |
| -16.00% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.14% | 16.05B | |
| +5.40% | 13.68B | |
| +33.29% | 12.17B |
- Stock Market
- Equities
- CDIO Stock
